DOI:

New York registry<br /> Invited commentary: <i>Christian Spaulding, Olivier Varenne</i>

Edward L. Hannan1, PhD; Chuntao Wu1, MD, PhD; Gary Walford2, MD; Alfred T. Culliford3, MD; Jeffrey P. Gold4, MD; Craig R. Smith5, MD; Robert S.D. Higgins6, MD; Russell E. Carlson7, MD; Robert H. Jones8, MD

Abstract from the New York registry

Abstract

Background: Numerous studies have compared the outcomes of two competing interventions for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and coronary stenting. However, little information has become available since the introduction of drug-eluting stents.

Methods: We identified patients with multivessel disease who received drug-eluting stents or underwent CABG in New York State between October 1, 2003, and December 31, 2004, and we compared adverse outcomes (death, death or myocardial infarction, or repeat revascularisation) through December 31, 2005, after adjustment for differences in baseline risk factors among the patients.

Results: In comparison with treatment with a drug-eluting stent, CABG was associated with lower 18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Among patients with three-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.80 (95% confidence interval [CI], 0.65 to 0.97) and the adjusted survival rate was 94.0% versus 92.7% (P = 0.03); the adjusted hazard ratio for death or myocardial infarction was 0.75 (95% CI, 0.63 to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1% versus 89.7% (P<0.001). Among patients with two-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.71 (95% CI, 0.57 to 0.89) and the adjusted survival rate was 96.0% versus 94.6% (P = 0.003); the adjusted hazard ratio for death or myocardial infarction was 0.71 (95% CI, 0.59 to 0.87) and the adjusted rate of survival free from myocardial infarction was 94.5% versus 92.5% (P<0.001). Patients undergoing CABG also had lower rates of repeat revascularisation.

Conclusions: For patients with multivessel disease, CABG continues to be associated with lower mortality rates than does treatment with drug-eluting stents and is also associated with lower rates of death or myocardial infarction and repeat revascularisation.

N Engl J Med. 2008 Jan 24;358(4):331-41. Copyright © 2008 Massachusetts Medical Society. All rights reserved.

Acknowledgement

Reprinted from The New England Journal of Medicine, Volume 358:331 January 24, 2008 Number 04, with permission from Massachusetts Medical Society.

Commentary on the New York registry

Comparisons between coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) in patients with multivessel disease is most certainly one of the most controversial and impassioned issues in contemporary cardiology. Several randomised trials performed in the 80 and 90’s repeatedly showed less repeat revascularisations after CABG1. Analysis of the diabetic subgroup from the BARI trial showed a higher mortality after PCI2. As a consequence, CABG remains the gold (or even platinum) standard in the treatment of multivessel disease in current guidelines. However, since the advent of drug eluting stents (DES), an increasing number of patients with mutlivessel disease are treated with PCI. Despite the obvious rationale of using a technique which has proven its efficacy in reducing the need for repeat revascularisation, there is currently limited data to support this practice. The ARTS II study compared a registry of contemporary patients treated with DES to patients included in the ARTS I randomised study comparing CABG and PCI with bare metal stents3. Outcome at one year showed highly favorable results in the DES patients. However, the conclusions are limited by the small amount of patients included.

Hannan et al used a registry from the New York state and identified patients with multivessel disease who received DES or underwent CABG in New York State between October 1, 2003, and December 31, 20044. After adjustment for differences in baseline risk factors by propensity analysis, they compared adverse outcomes (death, death or myocardial infarction, or repeat revascularisation) through December 31, 2005. In comparison with PCI with DES, CABG was associated with lower adjusted18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Repeat revascularisation was lower after CABG in all groups.

Are we on a dangerous path when we choose PCI with DES for treatment of multivessel disease? Hannan et al should be commended for performing an elaborate analysis on a large registry study. To compensate for the lack of randomisation and differences in baseline characteristics, the authors attempted to equalize the two groups by using propensity analysis. However, no statistical technique can adjust for the judgment of the treating physician which remains the most important factor leading to the choice of revascularisation technique. In fact, a major finding of the study was clearly overviewed by the authors: non-adjusted mortality rates were quite similar in both treatment groups, even in patients with diabetes. This clearly shows that patients were appropriately selected before treatment. Finally, although propensity analysis is valuable in assessing differences between groups, propensity-score matching might have been more appropriate5.

Several randomised trials comparing PCI with DES and CABG are ongoing. Their results will most certainly be the basis of our future decisions in patients with multivessel disease. Until then, adjusted data from registries will provide interesting insights on our practice and patient selection process.

Volume 4 Supplement C
Aug 20, 2008
Volume 4 Supplement C
View full issue


Key metrics

Suggested by Cory

Debate

10.4244/EIJ-E-25-00009 Jun 16, 2025
Guideline recommendations for QFR should be revisited: pros and cons
Fearon W and Biscaglia S

Flashlight

10.4244/EIJ-D-24-00795 Jun 16, 2025
Transcaval transcatheter aortic valve implantation via left-sided venous access
Doyle C and Casserly I

Letter to the editor

10.4244/EIJ-D-25-00325 Jun 16, 2025
Reply: Completeness or complexity? A nuanced reflection on multivessel revascularisation
Laudani C et al
free

Letter to the editor

10.4244/EIJ-D-25-00197 Jun 16, 2025
Letter: Completeness or complexity? A nuanced reflection on multivessel revascularisation
Sticchi A and Biondi-Zoccai G
free

Research Correspondence

10.4244/EIJ-D-24-01048 Jun 16, 2025
Next-day and 48-hour discharge following alternative access for transcatheter aortic valve implantation
Zendo Y et al
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
91.35

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved